Abstract | BACKGROUND/AIMS: METHODS: db/db mice were raised untreated until 17 weeks of age, by which time increase of urinary albumin was noted, and then treated with SMP-534 and/or losartan for another 8 weeks. Biochemical and histological analyses were performed at 25 weeks of age. RESULTS: Combined treatment with SMP-534 and losartan markedly prevented the increase of urinary albumin and ameliorated the progression of mesangial matrix expansion, even when administration was started long after the increase of urinary albumin. CONCLUSION:
|
Authors | Eiji Sugaru, Tsutomu Nakagawa, Michiko Ono-Kishino, Jun Nagamine, Teruhisa Tokunaga, Makoto Kitoh, W Ewan Hume, Ryu Nagata, Mutsuo Taiji |
Journal | Nephron. Experimental nephrology
(Nephron Exp Nephrol)
Vol. 105
Issue 2
Pg. e45-52
( 2007)
ISSN: 1660-2129 [Electronic] Switzerland |
PMID | 17139189
(Publication Type: Journal Article)
|
Copyright | Copyright 2007 S. Karger AG, Basel. |
Chemical References |
- Antihypertensive Agents
- Benzamides
- SMP-534
- Losartan
|
Topics |
- Albuminuria
- Animals
- Antihypertensive Agents
(pharmacology)
- Benzamides
(pharmacology)
- Diabetic Nephropathies
(drug therapy)
- Disease Models, Animal
- Drug Therapy, Combination
- Fibrosis
(drug therapy)
- Losartan
(pharmacology)
- Male
- Mice
|